Home > > > > > Report Detail

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018

Publisher Name :
Date: 01-Oct-2018
No. of pages: 470
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading companies.

Comprehensive directory of personalized medicine in oncology deals since 2012

Personalized medicine in oncology contract documents

Personalized medicine in oncology agreement terms

Personalized medicine in oncology agreement structure

Top personalized medicine in oncology deals by value

Most active personalized medicine in oncology dealmakers

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2012, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2012. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2012. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report scope

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 includes:

Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2012

Analysis of personalized medicine in oncology deal structure

Case studies of real-life personalized medicine in oncology deals

Access to over 700 personalized medicine in oncology deals

The leading personalized medicine in oncology deals by value since 2012

Most active personalized medicine in oncology dealmakers since 2012

The leading personalized medicine in oncology partnering resources

In Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018, the available contracts are listed by:

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Specific technology target

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Benefits

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of personalized medicine in oncology deal trends since 2012

Analysis of the structure of personalized medicine in oncology agreements with numerous real life case studies

Comprehensive access to over 700 personalized medicine in oncology deals entered into by the world's biopharma companies

Detailed access to actual personalized medicine in oncology contracts entered into by leading biopharma companies

Insight into the terms included in a personalized medicine in oncology agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine in Oncology dealmaking
2.1. Introduction
2.2. Personalized Medicine in Oncology partnering over the years
2.3. Most active Personalized Medicine in Oncology dealmakers
2.4. Personalized Medicine in Oncology partnering by deal type
2.5. Personalized Medicine in Oncology partnering by therapy area
2.6. Deal terms for Personalized Medicine in Oncology partnering
2.6.1 Personalized Medicine in Oncology partnering headline values
2.6.2 Personalized Medicine in Oncology deal upfront payments
2.6.3 Personalized Medicine in Oncology deal milestone payments
2.6.4 Personalized Medicine in Oncology royalty rates

Chapter 3 - Leading Personalized Medicine in Oncology deals
3.1. Introduction
3.2. Top Personalized Medicine in Oncology deals by value

Chapter 4 - Most active Personalized Medicine in Oncology dealmakers
4.1. Introduction
4.2. Most active Personalized Medicine in Oncology dealmakers
4.3. Most active Personalized Medicine in Oncology partnering company profiles

Chapter 5 - Personalized Medicine in Oncology contracts dealmaking directory
5.1. Introduction
5.2. Personalized Medicine in Oncology contracts dealmaking directory

Chapter 6 - Personalized Medicine in Oncology dealmaking by technology type
Biomarkers
Companion diagnostics
Personalised medicine
Pharmacogenomics

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Personalized Medicine in Oncology deals by company A-Z
Appendix 2 - Personalized Medicine in Oncology deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Appendix 3 - Personalized Medicine in Oncology deals by deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Spin out
Sub-license
Supply
Technology transfer
Appendix 4 - Personalized Medicine in Oncology deals by therapy area
Bladder cancer
Bone cancer
Brain cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial
Esophageal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Liver cancer
Lung cancer
Non small cell lung cancer
Lymphoma
Non Hodgkin's lymphoma
Melanoma
Mesothelioma
Metastases
Multiple myeloma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Sarcoma
Solid tumors
Symptoms
Oral mucositis
Testicular cancer
Thyroid cancer
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Tables and Figures

Figure 1: Personalized Medicine in Oncology partnering since 2012
Figure 2: Active Personalized Medicine in Oncology dealmaking activity- 2012 to 2018
Figure 3: Personalized Medicine in Oncology partnering by deal type since 2012
Figure 4: Personalized Medicine in Oncology partnering by disease type since 2012
Figure 5: Personalized Medicine in Oncology deals with a headline value
Figure 6: Personalized Medicine in Oncology deals with an upfront value
Figure 7: Personalized Medicine in Oncology deals with a milestone value
Figure 8: Personalized Medicine in Oncology deals with a royalty rate value
Figure 9: Top Personalized Medicine in Oncology deals by value since 2012
Figure 10: Most active Personalized Medicine in Oncology dealmakers 2012 to 2018
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs